Industry Experts Push for More Rigorous Clinical Trial Standards in Women’s Supplements

On October 16, 2026, NutraIngredients published coverage of CRN Convergence 2026 examining how women’s-health supplement research is tested and communicated. The conference’s SciComms Connect program took place on October 6, 2026, in Carlsbad, California.

Has the medical approach to midlife hair loss changed?

This was an industry research discussion, not a new clinical guideline for treating hair loss. The established approach described by the American Academy of Dermatology (AAD) remains an assessment of the cause rather than an assumption based on age or menopause.

According to the AAD, female pattern hair loss is hereditary and more common after menopause. Hormones may also play a role. The organisation recommends seeing a dermatologist to determine whether this condition or another explanation accounts for the thinning.

The conference’s relevance lies in the conversation about evidence: a product marketed for women should be judged against research relevant to those women. That is a standard for evaluating claims, not a replacement for diagnosis.

What did the conference coverage report?

NutraIngredients described presentations about the interpretation of women’s-health research. For readers weighing hair-growth claims, these were the central points:

• Collagen, probiotics and hair-growth formulations were discussed. Dr. Heather Woolery-Lloyd reviewed clinical research in these areas. Her presentation included research involving women experiencing hair thinning during perimenopause and menopause. Her central message was that supplements making claims for women should have been tested in women.
• Research participation needs a clear denominator. Kathryn Armstrong, chief scientific officer at USANA Health Sciences, challenged a frequently circulated sports-science statistic. According to NutraIngredients, she explained that the 6% figure referred to studies exclusively involving women. Women represented 34% of participants overall, she said. Studies conducted only in women and women’s participation across studies are different measures.
• Including women is not the same as describing hormonal status. Armstrong also cited an analysis of 1,826 sports-nutrition studies involving nearly 35,000 participants. According to the figures she presented, women represented 23% of participants. Only 14% of studies involving women reported menstrual status. These figures concern sports nutrition rather than hair-growth products, but they illustrate the distinction between female participation and meaningful detail about participants.
• A biological change needs careful interpretation. Dr. Madison Kackley of The Ohio State University said research involving women should account for hormonal status and metabolic response. Discussing ketogenic interventions in women with PCOS, she cautioned that a return of menstrual bleeding did not necessarily confirm ovulation. The example showed why an observed change should not be treated as proof of a different outcome.
• A measured nutrient level is not a demonstrated health benefit. Speakers discussed a prenatal study that assessed nutrient status without assessing maternal or infant clinical outcomes. This distinction matters when interpreting any health claim: the measure reported needs to match the benefit being claimed.

Where are the boundaries of this evidence?

The event report did not identify the individual collagen or probiotic studies or the hair-growth studies. It supplied neither sample sizes nor study durations. Doses and outcomes were also absent. The underlying sports-nutrition analysis was not identified by publication details or a link, so its figures remain statistics Armstrong cited rather than independently verified findings here.

Woolery-Lloyd is Nutrafol’s chief medical advisor, a commercial connection relevant to interpreting her presentation. That role is a reason for transparent appraisal, not proof that the research discussed was flawed. Taken together, the coverage does not establish that collagen or probiotics improve midlife hair outcomes. Nor does it establish a benefit for a particular hair-growth formulation.

What would useful hair-growth evidence need to show?

The practical value of this discussion is a more precise way to read a claim. The questions are about the match between the research and the promised benefit, rather than whether a product sounds scientific or uses familiar ingredients.

• Who took part? Evidence intended to support a claim for midlife women should describe the women studied. Were participants experiencing comparable thinning and a relevant stage of hormonal transition? “Tested in women” is a meaningful starting point, but the intended users should also be recognisable in the study population. A broad women’s-health label does not provide that detail.
• What exactly was tested? A clearly described formulation and dose allow a claim to be compared with the intervention used in the research. An ingredient category is not a full description of a product. The useful question is whether the evidence matches the formulation being promoted, rather than whether an ingredient has appeared somewhere in a research presentation. This is an evidence question, not a dosing recommendation.
• Which outcome was measured? A hair-growth claim needs an outcome that addresses hair. The reported result should be stated in its own terms rather than expanded into a broader promise. If the research measures a biological marker, the claim should identify that marker. Calling it a demonstrated improvement in appearance or health would require evidence for that outcome.
• Can the claim be traced to the research? Independent published trials provide material for examining participant details and reported outcomes together. A conference presentation can draw attention to research, while the original paper allows closer appraisal. The useful connection is between a specific promise and the evidence supporting it, not simply between a product and a scientific event.

Readers following developments in hair-loss trials can apply these questions to each reported advance. A research development deserves attention for what it actually measured, rather than for the range of hopes attached to it.

The same discipline belongs in discussions of midlife skin and collagen claims. Shared language about menopause or an ingredient should not make evidence for different outcomes interchangeable.

What does this mean for someone noticing thinning?

The AAD’s guidance brings the discussion back to the individual woman. Hair thinning after menopause may be female pattern hair loss, but the timing alone does not settle the explanation. A diagnosis matters because a claim about “menopause hair” does not identify the cause of someone’s hair loss.

The AAD lists disease and vitamin deficiency among possible explanations. Hormone imbalance and infection are others. Depending on the clinical assessment, blood tests or a scalp biopsy may be appropriate. Those are possibilities within an evaluation, not a routine checklist for every woman with thinning.

For persistent or concerning hair loss, the source-supported next step is assessment by a qualified dermatologist. The purpose is to establish what is happening before deciding which care is relevant. A supplement advertisement cannot perform that assessment, however closely its language seems to describe the reader’s life stage.

This approach does not dismiss appearance as a minor concern. Wanting to understand a change in hair is a legitimate reason to seek clear information. The useful distinction is between taking that concern seriously and assuming that buying a product is the necessary response.

How should a supplement claim be judged after this discussion?

The strongest editorial lesson is not that every supplement is ineffective or that every industry presentation is unreliable. Neither conclusion follows from this report. The more useful standard is that each claim should carry evidence specific enough to examine.

For a midlife hair-growth product, that means a visible connection between the intended users and the women studied. It also means a connection between the formulation promoted and the intervention tested. Finally, the outcome needs to address the benefit promised. Those connections make a claim assessable rather than merely appealing.

This keeps the conversation focused on the woman’s concern without turning menopause into a universal explanation. It also leaves room for a clear answer when the evidence is available, rather than treating scientific language itself as reassurance.

How should this shape future care?

The useful direction for clinical conversations is to pair a diagnosis of hair loss with supplement evidence that matches the woman and the claimed outcome.

How Refemina helps

Measurable changes in hair are the relevant outcome for hair-growth claims; Refemina translates credible research into clear adult guidance about midlife appearance. For women facing supplement or hormone pitches whenever their bodies change, the publication connects skin and hair with hormonal transition while distinguishing supported benefits from marketing and unresolved questions.

Explore Resources

Sources

1. Women's health research faces tougher questions at CRN Convergence 2026
2. www.aad.org › public › diseasesThinning hair and hair loss: Could it be female pattern hair ...
3. Hair loss: Diagnosis and treatment - American Academy of ...